A Case of Bing–Neel Syndrome Successfully Treated with Ibrutinib

Table 1

Summary of previously reported cases of ibrutinib use for the treatment of Bing–Neel syndrome.

Case report	Number of patients	Prior diagnosis of WM	Earlier BNS therapies	Ibrutinib dose	Length of response to ibrutinib
Cabannes-Hamy et al. [13]	2	Yes, yes	R/HD-MTX/L-AC → HDAC, R-DHAC → R	420 mg daily, 420 mg daily	6 months, 6 months
Mason et al. [14]	1	Yes	R/HD-MTX → B → L-AC	560 mg daily	23 months
Varettoni et al. [15]	1	No	BR/IT-MTX	Not reported	Not reported
Boudin et al. [16]	1	No	None	420 mg daily	11 months

BNS = Bing–Neel syndrome; WM = Waldenström macroglobulinemia; R = rituximab; HD-MTX = high-dose methotrexate; L-AC = intrathecal liposomal cytarabine; HDAC = high-dose cytarabine; R-DHAC = rituximab, dexamethasone, high-dose cytarabine, and carboplatin; B = bendamustine; BR = bendamustine and rituximab; IT-MTX = intrathecal methotrexate.